Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?

被引：4
|
作者：
Basalay, Maryna V. [1 ]
Davidson, Sean M. [1 ]
Yellon, Derek M. [1 ]
机构：
[1] UCL, Hatter Cardiovasc Inst, London, England
来源：
NEURAL REGENERATION RESEARCH | 2020年 / 15卷 / 10期
关键词：
D O I：
10.4103/1673-5374.280313
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
[No abstract available]
引用
收藏
页码：1852 / 1853
页数：2
相关论文
共 50 条
  • [31] Modern possibilities of pharmacotherapy of type 2 diabetes using analogues of glucagon-like peptide-1 (GLP-1)
    Shestakova, M., V
    Vikulova, O. K.
    DIABETES MELLITUS, 2007, 10 (01): : 9 - 15
  • [32] Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis
    Berg, Gabriela
    Barchuk, Magali
    Lobo, Martin
    Nogueira, Juan Patricio
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2022, 16 (09)
  • [33] Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases
    Andre F. Batista
    Victor Bodart-Santos
    Fernanda G. De Felice
    Sergio T. Ferreira
    CNS Drugs, 2019, 33 : 209 - 223
  • [34] Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases
    Batista, Andre F.
    Bodart-Santos, Victor
    De Felice, Fernanda G.
    Ferreira, Sergio T.
    CNS DRUGS, 2019, 33 (03) : 209 - 223
  • [35] Can epicardial fat glucagon-like peptide-1 receptor open up to the cardiovascular benefits of glucagon-like peptide-1 analogues?
    Iacobellis, Gianluca
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (03): : 224 - 225
  • [36] Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
    Unger J.R.
    Parkin C.G.
    Diabetes Therapy, 2011, 2 (1) : 29 - 39
  • [37] Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons
    Kawatani, Masahiro
    Yamada, Yuichiro
    Kawatani, Masahito
    PEPTIDES, 2018, 107 : 68 - 74
  • [38] Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands
    Tanday, Neil
    Flatt, Peter R.
    Irwin, Nigel
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 526 - 541
  • [39] The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis
    Li, Ya-Kun
    Ma, Dong-Xia
    Wang, Zhi-Min
    Hu, Xiao-Fan
    Li, Shang-Lin
    Tian, Hong-Zhe
    Wang, Meng-Jun
    Shu, Yan-Wen
    Yang, Jun
    PHARMACOLOGICAL RESEARCH, 2018, 131 : 102 - 111
  • [40] Somatostatin is a major, paracrine regulator of glucagon-like peptide-1 (GLP-1) secretion
    Hansen, L
    Mineo, H
    Bisgaard, T
    Jorgensen, PN
    Holst, JJ
    DIABETOLOGIA, 1997, 40 : 498 - 498
12345